Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 250

Sort by

Sort Order Select

Journal Articles

DNTT-mediated DNA Damage Response Drives Inotuzumab Ozogamicin Resistance in B-cell Acute Lymphoblastic Leukemia

Blood blood.2024026085.

https://doi.org/10.1182/blood.2024026085

Published: 2024

Includes: Supplemental data

Journal Articles

Affinity-Tuned T-Cell Engager for Dual Targeting of B-Myeloid Mixed-Phenotype Acute Leukemia (B-MPAL)

Sophie Jamet, Huiyuan Zhang, Sally Ditzler, Kikki Tucker, Peter Chong, Clara Libbrecht, Ray Ruff, Hailey Hentschel, Bianka Haro, Benjamin J Huang, James Olson, Jason Price, Mignon L. Loh

Blood (2024) 144 (Supplement 1): 90.

https://doi.org/10.1182/blood-2024-209377

Published: 2024

Journal Articles

EBF1 Activity Controls Leukemia Sensitivity to Inotuzumab Ozogamicin

Carolin S. Escherich, Zhenhua Li, Kelly R. Barnett, Yizhen Li, Megan Walker, Wenjian Yang, Xin Huang, Jiyang Yu, Wendy Stock, Elisabeth Paietta, Marina Konopleva, Steven M. Kornblau, Mark R. Litzow, Hiroto Inaba, Ching-Hon Pui, Mignon L. Loh, Daniel Savic, Jun J. Yang

Blood (2024) 144 (Supplement 1): 830.

https://doi.org/10.1182/blood-2024-198800

Published: 2024

Journal Articles

Diagnosing and Staging Central Nervous System Involvement in Pediatric ALL: A Global Survey on Its Heterogeneity

Laura Almási, Cornelia Eckert, Maria Thastrup, Vera Münch, Dániel Maszárovics, Bernadett Hon-Balla, Lennart Lenk, Gábor Barna, Wenyu Yang, Mignon L. Loh, Hyoung Jin Kang, Sophia Polychronopoulou, Arja Harila, Marko Kavcic, Kjeld Schmiegelow, Lüder Hinrich Meyer, Christina Halsey, Daniel J Erdelyi

Blood (2024) 144 (Supplement 1): 2805.

https://doi.org/10.1182/blood-2024-201255

Published: 2024

Journal Articles

Examining Disparities By Race, Ethnicity, and Socioeconomic Factors in Children and Young Adults with Relapsed Acute Lymphoblastic Leukemia: A Report from the Children's Oncology Group

Blood (2024) 144 (Supplement 1): 2797.

https://doi.org/10.1182/blood-2024-193893

Published: 2024

Journal Articles

Utility of a Second Interim Maintenance Phase to Improve Outcomes for Pediatric Acute Lymphoblastic Leukemia: A Report from the Children's Oncology Group

Blood (2024) 144 (Supplement 1): 2813.

https://doi.org/10.1182/blood-2024-194872

Published: 2024

Journal Articles

Additional Induction Intrathecal Cytarabine for Patients with CNS2 Disease at Diagnosis Is Not Beneficial for Patients with B-ALL Treated on Children's Oncology Group Protocols AALL0932 and AALL1131

Cathy A. Lee-Miller, John A. Kairalla, Emily Hibbitts, Naomi J. Winick, Anne Angiolillo, Reuven J. Schore, Wanda L. Salzer, Michael J. Burke, Mignon L. Loh, Elizabeth A. Raetz, Stephen P. Hunger, Meenakshi Devidas, David T. Teachey, Sumit Gupta, Jennifer L. McNeer

Blood (2024) 144 (Supplement 1): 4195.

https://doi.org/10.1182/blood-2024-203456

Published: 2024

Journal Articles

Interferon-Activated Gene Signatures Associate with Chemotherapy Resistance and Sensitivity to JAK-Inhibition in Refractory ETP-ALL

Blood (2024) 144 (Supplement 1): 1464.

https://doi.org/10.1182/blood-2024-211090

Published: 2024

Journal Articles

Blinatumomab Added to Chemotherapy Improves Disease-Free Survival in Newly Diagnosed NCI Standard Risk Pediatric B-Acute Lymphoblastic Leukemia: Results from the Randomized Children's Oncology Group Study AALL1731

Blood (2024) 144 (Supplement 1): 1.

https://doi.org/10.1182/blood-2024-207450

Published: 2024

Journal Articles

Prognostic Impact of t(1;19) in Pediatric B-Cell Acute Lymphoblastic Leukemia (B-ALL) Patients Treated on Contemporary Children's Oncology Group (COG) Protocols

Ashley Pinchinat, John A. Kairalla, Meenakshi Devidas, Andrew J. Carroll, Mary Shago, Anne Angiolillo, Michael J. Burke, Wanda L. Salzer, Naomi J. Winick, Mignon L. Loh, David T. Teachey, Elizabeth A. Raetz, Karen R Rabin, Rachel E. Rau, Sumit Gupta

Blood (2024) 144 (Supplement 1): 315.

https://doi.org/10.1182/blood-2024-198507

Published: 2024

Journal Articles

Genomic Biomarkers of Poor Outcome in Patients with T-Cell Lymphoblastic Lymphoma

Blood (2024) 144 (Supplement 1): 313.

https://doi.org/10.1182/blood-2024-203827

Published: 2024

Journal Articles

TCL1A Is Associated with Blinatumomab Response and Immune Activation in Pediatric B-ALL

Blood (2024) 144 (Supplement 1): 634.

https://doi.org/10.1182/blood-2024-203756

Published: 2024

Journal Articles

Germ line genetic NBN variation and predisposition to B-cell acute lymphoblastic leukemia in children

Carolin S. Escherich, Wenan Chen, Yizhen Li, Wenjian Yang, Rina Nishii, Zhenhua Li, Elizabeth A. Raetz, Meenakshi Devidas, Gang Wu, Kim E. Nichols, Hiroto Inaba, Ching-Hon Pui, Sima Jeha, Bruce M. Camitta, Eric Larsen, Stephen P. Hunger, Mignon L. Loh, Jun J. Yang

Blood (2024) 143 (22): 2270–2283.

https://doi.org/10.1182/blood.2023023336

Published: 2024

Includes: Supplemental data

Journal Articles

MRD at the end of induction and EFS in T-cell lymphoblastic lymphoma: Children’s Oncology Group trial AALL1231

Blood (2024) 143 (20): 2053–2058.

https://doi.org/10.1182/blood.2023021184

Published: 2024

Includes: Supplemental data

Journal Articles

Prognostic significance of ETP phenotype and minimal residual disease in T-ALL: a Children’s Oncology Group study

Brent L. Wood, Meenakshi Devidas, Ryan J. Summers, Zhiguo Chen, Barbara Asselin, Karen R. Rabin, Patrick A. Zweidler-McKay, Naomi J. Winick, Michael J. Borowitz, William L. Carroll, Elizabeth A. Raetz, Mignon L. Loh, Stephen P. Hunger, Kimberly P. Dunsmore, David T. Teachey, Stuart S. Winter

Blood (2023) 142 (24): 2069–2078.

https://doi.org/10.1182/blood.2023020678

Published: 2023

Includes: Supplemental data

Journal Articles

Feasibility and Outcome of Post-Induction Therapy Incorporating Dasatinib for Patients with Newly Diagnosed ABL-Class Fusion B-Lymphoblastic Leukemia (ABL-class Fusion B-ALL): Children's Oncology Group AALL1131

Blood (2023) 142 (Supplement 1): 961.

https://doi.org/10.1182/blood-2023-190495

Published: 2023

Journal Articles

CXCR3/CXCL10 Signaling Pathway Drives T-ALL into the CNS/Meningeal Microenvironment

Nitesh D. Sharma, Esra'a Keewan, Wojciech Ornatowski, Monique Nysus, Silpita Paul, Quiteria Jacquez, Bianca L. Myers, Huining Kang, Katherine E. Zychowski, Stuart S Winter, Stephen P. Hunger, Mignon L. Loh, Eliseo Castillo, Tou Vue, Nicholas Jones, Panagiotis Ntziachristos, Ksenia Matlawska-Wasowska

Blood (2023) 142 (Supplement 1): 37.

https://doi.org/10.1182/blood-2023-189951

Published: 2023

Journal Articles

Next-Generation Sequencing (NGS) for Residual Disease (MRD) Monitoring in T-Lymphoblastic Leukemia (T-ALL)

Ntasha Roy, Zhengwei (Jenny) Mao, Chang Xu, David T. Teachey, Zhiguo (Bruce) Chen, Meenakshi Devidas, Xueyan Chen, Elizabeth A. Raetz, Mignon L. Loh, Stephen P. Hunger, Brent L. Wood

Blood (2023) 142 (Supplement 1): 2976.

https://doi.org/10.1182/blood-2023-190624

Published: 2023

Journal Articles

Patients with Down Syndrome and High-Risk B-Acute Lymphoblastic Leukemia Demonstrate Improved Outcomes on a Modified Chemotherapy Regimen: A Report from Children's Oncology Group Study AALL1131

Vilmarie Rodriguez, Meenakshi Devidas, Zhiguo (Bruce) Chen, Andrew J Carroll, Nyla A. Heerema, Michael J. Borowitz, Brent L. Wood, William L. Carroll, Naomi J Winick, Elizabeth A. Raetz, Mignon L. Loh, Michael J. Burke, Wanda L. Salzer, Stephen P. Hunger, Karen R. Rabin

Blood (2023) 142 (Supplement 1): 824.

https://doi.org/10.1182/blood-2023-185368

Published: 2023

Journal Articles

Efficacy of the Allosteric MEK Inhibitor Trametinib in Relapsed and Refractory Juvenile Myelomonocytic Leukemia: A Report from the Children's Oncology Group

Elliot Stieglitz, Alex Lee, Steven P. Angus, Christopher Davis, Donald Barkauskas, David Hall, Scott C. Kogan, Julia Meyer, Steven D. Rhodes, Xiaoling Xuei, Kevin Shannon, Mignon L. Loh, Elizabeth Fox, Brenda J. Weigel

Blood (2023) 142 (Supplement 1): 74.

https://doi.org/10.1182/blood-2023-173153

Published: 2023

NARROW

DNTT-mediated DNA Damage Response Drives Inotuzumab Ozogamicin Resistance in B-cell Acute Lymphoblastic Leukemia

Affinity-Tuned T-Cell Engager for Dual Targeting of B-Myeloid Mixed-Phenotype Acute Leukemia (B-MPAL)

EBF1 Activity Controls Leukemia Sensitivity to Inotuzumab Ozogamicin

Diagnosing and Staging Central Nervous System Involvement in Pediatric ALL: A Global Survey on Its Heterogeneity

Examining Disparities By Race, Ethnicity, and Socioeconomic Factors in Children and Young Adults with Relapsed Acute Lymphoblastic Leukemia: A Report from the Children's Oncology Group

Utility of a Second Interim Maintenance Phase to Improve Outcomes for Pediatric Acute Lymphoblastic Leukemia: A Report from the Children's Oncology Group

Additional Induction Intrathecal Cytarabine for Patients with CNS2 Disease at Diagnosis Is Not Beneficial for Patients with B-ALL Treated on Children's Oncology Group Protocols AALL0932 and AALL1131

Interferon-Activated Gene Signatures Associate with Chemotherapy Resistance and Sensitivity to JAK-Inhibition in Refractory ETP-ALL

Blinatumomab Added to Chemotherapy Improves Disease-Free Survival in Newly Diagnosed NCI Standard Risk Pediatric B-Acute Lymphoblastic Leukemia: Results from the Randomized Children's Oncology Group Study AALL1731

Prognostic Impact of t(1;19) in Pediatric B-Cell Acute Lymphoblastic Leukemia (B-ALL) Patients Treated on Contemporary Children's Oncology Group (COG) Protocols

Genomic Biomarkers of Poor Outcome in Patients with T-Cell Lymphoblastic Lymphoma

TCL1A Is Associated with Blinatumomab Response and Immune Activation in Pediatric B-ALL

Germ line genetic NBN variation and predisposition to B-cell acute lymphoblastic leukemia in children

MRD at the end of induction and EFS in T-cell lymphoblastic lymphoma: Children’s Oncology Group trial AALL1231

Prognostic significance of ETP phenotype and minimal residual disease in T-ALL: a Children’s Oncology Group study

Feasibility and Outcome of Post-Induction Therapy Incorporating Dasatinib for Patients with Newly Diagnosed ABL-Class Fusion B-Lymphoblastic Leukemia (ABL-class Fusion B-ALL): Children's Oncology Group AALL1131

CXCR3/CXCL10 Signaling Pathway Drives T-ALL into the CNS/Meningeal Microenvironment

Next-Generation Sequencing (NGS) for Residual Disease (MRD) Monitoring in T-Lymphoblastic Leukemia (T-ALL)

Patients with Down Syndrome and High-Risk B-Acute Lymphoblastic Leukemia Demonstrate Improved Outcomes on a Modified Chemotherapy Regimen: A Report from Children's Oncology Group Study AALL1131

Efficacy of the Allosteric MEK Inhibitor Trametinib in Relapsed and Refractory Juvenile Myelomonocytic Leukemia: A Report from the Children's Oncology Group

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only